Pluri Congratulates Mesoblast on FDA Approval of First Mesenchymal Stromal Cell Therapy for Steroid-Refractory Acute Graft-Versus-Host Disease

Core Viewpoint - The FDA's approval of the first MSC-based therapy for steroid-refractory acute graft-versus-host disease (SR-aGVHD) represents a significant advancement in regenerative medicine and highlights the potential of MSC therapies [1][2] Company Overview - Pluri Inc. is focused on developing innovative cell-based technologies and has a proprietary 3D cell-expansion platform that enables scalable and robust cell-based therapies [2][4] - The company aims to address critical unmet medical needs through its advanced cell therapy product candidates, including PLacental eXpanded cells for various indications [3][4] Industry Impact - The FDA approval is seen as a milestone not only for Mesoblast but for the entire field of cellular medicine, emphasizing the transformative potential of MSC therapies in healthcare [2][3] - Regenerative medicine is positioned to shift the healthcare paradigm from managing chronic conditions to enabling true healing and regeneration, potentially improving patient outcomes and creating more sustainable healthcare systems [2][3] Future Aspirations - Pluri is committed to expanding the therapeutic boundaries of cell-based solutions and accelerating the development of MSC-based therapies globally [3][4] - The company envisions a future where cell-based technologies can transform lives across a spectrum of diseases, leveraging its expertise to pioneer new treatments [3]